Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Liabilities
Everything the company owes to creditors and other parties.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 73.6% from a year ago
Total liabilities stood at $2.59M at the end of Q1 FY2026, up 73.6% from a year earlier and down 10.4% from the prior quarter. Over 3 fiscal years it compounded at -2.7% a year.
Context
- Total liabilities amounted to 1.9% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +73.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.89M USD
- Year-over-year change
- -45.0%
- 4-year CAGR
- +16.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89M | -45.0% |
| FY2024 | 2024-12-31 | 5.25M | +199.0% |
| FY2023 | 2023-12-31 | 1.76M | -44.0% |
| FY2022 | 2022-12-31 | 3.14M | +98.5% |
| FY2021 | 2021-12-31 | 1.58M | — |
Total Liabilities vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +73.6% is the 2nd highest of 11, against a peer median of -13.1%.
- Total liabilities amounts to 1.9% of total assets for MNPR, versus a peer median of 27.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $918.16M USD | +1089.2% | -20.6% | 78.0% | |
| Mar 2026 | $507.87M USD | -0.6% | +7.4% | 174.2% | |
| Jun 2026 | $221.73M USD | -14.4% | +26.4% | 30.6% | |
| Mar 2026 | $196.68M USD | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | $98.08M USD | -31.7% | -8.4% | 15.0% | |
| Dec 2025 | €84.39M EUR | -17.4% | -18.1% | 134.6% | |
| Sep 2026 | $51.22M USD | +44.5% | +87.6% | 10.1% | |
| Mar 2026 | $26.98M USD | -17.2% | -8.4% | 15.1% | |
| Mar 2026 | $18.7M USD | -11.7% | +8.2% | 9.1% | |
| Jun 2026 | $9.86M USD | -77.6% | -2.7% | 24.5% | |
| Mar 2026 | $2.59M USD | +73.6% | -2.7% | 1.9% | |
| Peer median (excluding MNPR) | — | -13.1% | +2.3% | 27.6% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.